Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors

NCT07223125 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT07223125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1
Overall status
Recruiting
Start date
October 10, 2025
Completion date
August 15, 2028
Enrollment
360 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced-stage solid tumors